The Week in Review: Sinopharm to Raise $640 Million through Bond Sale
Sinopharm Holdings, one of China’s big-three drug distributors, will issue $640 million of five-year corporate bonds that may be used to fund new acquisitions; Shanghai Fosun Pharma will buy $22.4 million of preferred stock in Saladax Biomedical, a US maker of diagnostic assays; EntreMed, a US biotech with strong China connections, raised $10.7 million from two China-specific institutional investment funds; Viva Biotech, a Shanghai pre-clinical CRO, formed a drug development partnership with Addex Therapeutics of Switzerland; China National Biotec Group announced a research collaboration with Riboxx Pharma, a German biopharma; WuXi PharmaTech signed a second agreement with OMT, a California company that produces transgenic animals; Sun Yat-sen University will collaborate with Johns Hopkins University to develop China’s next-generation clinical investigators; China may give the SFDA power to regulate the nation’s food supply in addition to drugs; and WuXi PharmaTech reported another year of steadily increasing growth for 2012, something it seems to do with metronomic regularity. More details…. Stock Symbols: (HK: 01099) (SHA: 600196; HK: 02196) (NSDQ: ENMD) (NYSE: WX) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here